PRAX Praxis Precision Medicines, Inc.

company

SEC Filings & Insider Trading Activity 2026

Business Overview

• • Core business: Precision neuroscience biopharma developing therapies for CNS disorders from genetic epilepsies via two platforms, Cerebrum™ (small molecules) and Solidus™ (antisense oligonucleotides)
• • New emphasis on clinical development with four clinical-stage candidates; submitted NDAs for ulixacaltamide (essential tremor) and relutrigine (SCN2A-DEE, SCN8A-DEE)
• • Strategic shift to expanded clinical and commercial preparations for NDA-stage assets and ongoing Phase 3 programs (POWER1, POWER2 for vormatrigine) targeting broader epilepsy and CNS disorders
• • Quantitative highlight: ~7 million US essential tremor patients, 54% median seizure reduction in RADIANT vormatrigine Phase 2, 53% placebo-adjusted seizure reduction with relutrigine in EMBOLD Phase 2
• • Noteworthy: FDA granted Breakthrough Therapy Designation for ulixacaltamide and relutrigine; first commercial collaboration in Greater China for ulixacaltamide launched

Risk Factors

• • Regulatory risk: ongoing FDA review of NDAs for ulixacaltamide (essential tremor) and relutrigine (SCN2A and SCN8A DEEs) with uncertain approval timing or outcome
• • Macroeconomic exposure: cash runway extends into 2028 but risks of faster cash burn due to increased R&D, clinical trials, or unexpected costs
• • Supply chain vulnerability: potential delays or failure in manufacturing scale-up or third-party clinical/commercial supply arrangements
• • Competitive risk: failure to address competing technologies or market acceptance risks amid evolving neurology drug landscape
• • Financial risk: accumulated deficit $1.1 billion with net losses $303.3 million in 2025 and $182.8 million in 2024, requiring additional capital raising that could dilute shareholders

Management Discussion & Analysis

• • No revenues reported; focused on R&D and pre-commercial activities with expected substantial operating expense increases
• • Operating losses expected to grow due to advancing clinical trials, commercialization prep, and infrastructure buildout; no margin % disclosed
• • No segment performance breakdown; primary activities in Cerebrum™ and Solidus™ platforms with collaborative IP licensing arrangements
• • Cash, cash equivalents, and marketable securities plus January 2026 follow-on offering proceeds expected to fund operations into 2028; lease and licensing commitments total $1.6M plus milestone payments (e.g., $3.0M to RogCon, $6.9M to Ionis)
• • Risks: high R&D costs, uncertainty of approval and commercialization, potential need for additional capital with dilution risk, market volatility affecting funding access

What are the latest PRAX SEC filings in 2026?

Praxis Precision Medicines, Inc. (PRAX) has filed a 10-K annual report on February 19, 2026, a 10-Q quarterly report on May 7, 2026, an 8-K current report on July 7, 2026 with the SEC. SignalX tracks every new SEC EDGAR filing daily, including 10-K, 10-Q, 8-K, and Form 4 insider transactions, with AI-powered summaries of key sections.

When did PRAX file its most recent 10-K annual report?

Praxis Precision Medicines, Inc. (PRAX) filed its most recent 10-K annual report on February 19, 2026. The 10-K includes audited financial statements, business overview, risk factors, and management discussion, all available on SignalX with AI-generated summaries and XBRL financial data.

How do I view PRAX 10-Q quarterly reports?

Praxis Precision Medicines, Inc. (PRAX)'s most recent 10-Q quarterly report was filed on May 7, 2026. SignalX displays every PRAX 10-Q with AI-generated summaries of the MD&A (Management Discussion & Analysis) and Risk Factors sections, plus links to the original SEC EDGAR document.

What 8-K current reports has PRAX filed recently?

Praxis Precision Medicines, Inc. (PRAX)'s most recent 8-K was filed on July 7, 2026. 8-K filings disclose material corporate events such as earnings releases, executive changes, mergers, and other significant developments. SignalX surfaces each 8-K with item-level summaries so you can quickly see what happened.

Where can I find PRAX insider trading activity (Form 4)?

SignalX aggregates every PRAX Form 4 insider transaction from SEC EDGAR. Form 4 reports show when officers, directors, and 10% shareholders buy or sell company stock, with transaction code, share count, and price per share.

How often does PRAX file with the SEC?

Praxis Precision Medicines, Inc. (PRAX) files a 10-K annual report once per year (typically within 60 days of fiscal year-end) and 10-Q quarterly reports three times per year. 8-K current reports are filed as needed when material events occur, and Form 4 insider transaction reports are due within two business days of a trade. SignalX monitors SEC EDGAR daily to surface every new PRAX filing with AI-powered analysis.

What is the difference between 10-K, 10-Q, and 8-K SEC filings?

A 10-K is a comprehensive annual report with audited financials, business overview, and risk factors. A 10-Q is a shorter quarterly report with unaudited financials and management discussion. An 8-K is a current report filed when a material event occurs, such as earnings releases, executive changes, acquisitions, or other significant developments. SignalX provides AI-generated summaries for all three filing types for Praxis Precision Medicines, Inc. (PRAX).

What is PRAX's SEC CIK number?

Praxis Precision Medicines, Inc. (PRAX)'s SEC CIK (Central Index Key) number is 1689548. The CIK is a unique identifier assigned by the SEC to every filing entity. You can use CIK 1689548 to look up all PRAX filings on SEC EDGAR, or browse them here on SignalX with AI-powered analysis.

Where can I find PRAX return on equity (ROE) and financial data?

SignalX extracts XBRL financial data from Praxis Precision Medicines, Inc. (PRAX) 10-K annual filings, including revenue, net income, gross profit, operating income, EPS, total assets, stockholders' equity, and operating cash flow. Return on equity (ROE) can be derived from net income divided by stockholders' equity. Multi-year financial trends are displayed in the Financial Summary table above.